AML Therapy with Irradiated Allogeneic Cells

Print this page

AML Therapy with Irradiated Allogeneic Cells

Efficacy of allogeneic irradiated cells as consolidation therapy for patients with AML after fludarabine-cytarabine induction chemotherapy for patients with relapsed or refractory AML, age > 60 years old.

Protocol Number021208
Principal InvestigatorRoger Strair
PhasePilot
ScopeLocal
Applicable Disease SitesMyeloid and Monocytic Leukemia
Therapies InvolvedBone Marrow Transplant
Chemotherapy multiple agents systemic
Drugs InvolvedCYTARABINE
FLUDARABINE
Donor Lymphocyte Infusion
Participating InstitutionsRutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.